Advances in emerging drugs for the treatment of neuroblastoma.

Pablo Berlanga, Adela Cañete, Victoria Castel

Expert opinion on emerging drugs 2017 Mar

filter terms:

Neuroblastoma is the most common solid extracranial tumor of childhood. Outcome for children with high-risk neuroblastoma remains suboptimal. More than half of children diagnosed with high-risk neuroblastoma either do not respond to conventional therapies or relapse after treatment with dismal prognosis. Areas covered: This paper presents a short review of the state of the art in the current treatment of high-risk neuroblastoma. An updated review of new targeted therapies in this group of patients is also presented. Expert opinion: In order to improve prognosis for high-risk patients there is an urgent need to better understand spatial and temporal heterogeneity and obtain new predictive preclinical models in neuroblastoma. Combination strategies with conventional chemotherapy and/or other targeted therapies may overcome current ALK inhibitors resistance. Improvement of international and transatlantic cooperation to speed clinical trials accrual is needed.

Citation

Pablo Berlanga, Adela Cañete, Victoria Castel. Advances in emerging drugs for the treatment of neuroblastoma. Expert opinion on emerging drugs. 2017 Mar;22(1):63-75